A5064500437- Hemoglobinopathies and Related Disorders
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Iron Metabolism and Disorders
- Nonmelanoma Skin Cancer Studies
- Lung Cancer Research Studies
- Gastrointestinal disorders and treatments
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Cutaneous Melanoma Detection and Management
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Folate and B Vitamins Research
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Genetic factors in colorectal cancer
- Metastasis and carcinoma case studies
- Economic and Financial Impacts of Cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Adolescent and Pediatric Healthcare
Sanofi (United States)
2018-2025
Tris Pharma (United States)
2011-2018
Novartis (United States)
2011-2018
Novartis (Switzerland)
2011-2017
HealthInsight
2012
Hackensack University Medical Center
2012
Health Outcomes Solutions (United States)
2010
Triangle
2002
The aim of the current study was to assess economic impact using next-generation sequencing (NGS) versus single-gene testing strategies among patients with metastatic non-small-cell lung cancer (mNSCLC) from perspective Centers for Medicare & Medicaid Services (CMS) and US commercial payers.A decision analytic model considered who were newly diagnosed mNSCLC received programmed death ligand 1 genomic alteration tests-EGFR, ALK, ROS1, BRAF, MET, HER2, RET, NTRK1-using upfront NGS (all...
This study explored the blood transfusion patterns, SCD complications, utilization of iron chelation therapies (ICT), healthcare resource use, and costs in pediatric, transitioning (18 years old) adult patients with SCD.Data from Florida (1998-2009), New Jersey (1996-2009), Missouri (1997-2010), Kansas (2001-2009), Iowa (1998-2010) state Medicaid were used. Patients ≥2 diagnoses ≥1 event included. Rates events, proportion eligible receiving ICT calculated. eligibility was defined as ≥10...
Background To provide pooled longer term data from three groups of a phase 2 study cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration response (DOR) impact on quality life (QoL). Methods Patients received 3 mg/kg every weeks (group 1, metastatic CSCC [mCSCC], n=59; group 2, locally CSCC, n=78) or 350 mg 3, mCSCC, n=56). Primary endpoint was objective rate (ORR) per independent central review (ICR). QoL repeatedly measured at day 1 each...
Objective:Brain metastases (BM) are highly prevalent among anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patients; yet little is known about their real-world treatment patterns and clinical economic burdens. This study aimed to describe these patients' patterns, symptoms, costs.Research design methods:Retrospective pooling data from three large administrative databases in the US (08/2011–06/2013). ALK+ NSCLC patients with BM continuous enrollment for ≥ 60 days...
Treatment advances for metastatic breast cancer (mBC) have improved overall survival (OS) in some mBC subtypes; however, there remains no cure mBC. Considering the use of progression-free (PFS) and other surrogate endpoints clinical trials, we must understand patient perspectives on measures used to assess treatment efficacy.To explore global perceptions concept PFS its potential relation quality life (QoL).Virtual roundtables Europe United States interviews Japan with patients, advocates,...
Aims: Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but benefits of iron chelation therapy have not been clearly demonstrated. We examined the association between deferasirox (DFX) and mortality in transfusion-receiving Medicare patients. Patients & methods: MDS from 2005 to 2008 were identified using ICD-9 codes 100% claims. receiving ≥20 blood units observed until death or end study. Marginal structural models used for estimation. Results: 3926 (10.1%...
Brain metastases among lung cancer patients can impair cognitive and functional ability, complicate care, reduce survival. This study focuses on the economic burden of brain metastasis in cancer-direct healthcare costs to payers indirect patients, payers, employers-in US.Retrospective using claims data from over 60 self-insured Fortune 500 companies across all US census regions (January 1999-March 2013). Adult, non-elderly with were evaluated two periods: (1) pre-diagnosis (≤30 days prior...
In 2018, cemiplimab-rwlc became the first systemic treatment approved by US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates curative surgery radiation. 2019, conditional approvals were granted Health Canada and European Commission same indications. Limited data exist pertaining to clinical characteristics, disease progression survivorship of in real-world practice. CemiplimAb-rwlc Survivorship Epidemiology (CASE) is a...
BACKGROUND: Recent retrospective studies suggest myelodysplastic syndromes (MDSs) are more common than previously recognized and patients who develop transfusional dependence may be at risk for increased comorbid complications. STUDY DESIGN AND METHODS: A review was undertaken of Medicare claims focusing on costs associated with a new claim listing ICD‐9‐CM Diagnosis Code 238.7 in first quarter 2003. Patients were followed until 2005 to assess resource use costs. RESULTS: total 512 aged 65...
To evaluate the cost-effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) from a payer perspective United States.A partitioned survival model was developed to assess versus historical standard care (SOC). All inputs were identified based on systematic literature review, supplemented by expert opinion where necessary. Clinical for individual patient data phase 2 single-arm trial (NCT27060498). For SOC, analysis pooled clinical trials and retrospective...
Sub-optimal patient adherence to iron chelation therapy (ICT) may impact outcomes and increase cost of care. This study evaluated the economic burden ICT non-adherence in patients with sickle cell disease (SCD) or thalassemia.
Abstract Background Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experience side effects and reduced quality of life (QoL) discontinue ET. We sought to describe these issues develop a prediction model early discontinuation Methods Among with hormone receptor–positive HER2-negative stage I-III the Cancer Toxicities cohort (NCT01993498) who were prescribed ET between 2012 2017, upon stratification by menopausal status, we evaluated patterns including treatment...
Abstract Background Nontransfusion‐dependent thalassemia (NTDT) refers to a diverse group of mutations and clinical phenotypes that do not require chronic transfusions. It is increasingly prevalent in the United States. Procedure This study reviews epidemiology characteristics 138 patients with NTDT treated at four US centers from 1997 2014. Data on laboratory results, transfusions, complications were collected patient charts. Results Overall, 84 α‐thalassemia (62 deletional hemoglobin H; 22...
Abstract Purpose To assess real-world treatment patterns in patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (mBC) who received cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combination an aromatase inhibitor (AI) or fulvestrant at first line. Methods Patient characteristics, history, and outcomes data were extracted from the French ‘Système National des Données de Santé’ (SNDS) database for HR+/HER2- mBC...
Background:Limited post-crizotinib treatment options for ALK-positive non-small cell lung cancer (NSCLC) might lead to poor survival and high economic burden.Objective:To evaluate real-world patterns, overall (OS), costs following crizotinib discontinuation.Methods:This study used chart review claims data. First, 27 participating US oncologists reviewed medical records of NSCLC patients who discontinued monotherapy reported patient demographic clinical information, including mortality. OS...
Abstract Background In the EMPOWER‐Lung 1 trial ( ClinicalTrials.gov , NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed death‐ligand (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among participants. Methods Adults NSCLC and Eastern Cooperative Oncology Group performance status 0 to randomly assigned 350 mg every 3 weeks or chemotherapy. At baseline day of each treatment cycle,...
Recent clinical trial data have demonstrated that 3 years vs 1 year of adjuvant imatinib therapy for patients with surgically resected Kit+ Gastrointestinal Stromal Tumors (GIST) leads to a significant improvement in recurrence-free survival and overall survival. This study assesses the cost-effectiveness treating from US payer's perspective.A Markov model was developed predict GIST recurrence treatment costs. Patients enter after surgery transition among three health states: free...